2025年3月28日，Vertex Pharmaceuticals宣布终止其第二代1型糖尿病（T1D）细胞疗法VX-264的研发，这一消息无疑为糖尿病治疗领域的创新尝试蒙上了一层阴影。 尽管如此，Vertex并未放弃对糖尿病治疗的探索，其另一款疗法VX-880（zimislecel）仍在积极推进中，并已进入III期 ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...

Vertex Pharmaceuticals VRTX announced the clearance of an Investigational New Drug (IND) application by the FDA for VX-264, its novel encapsulated cell therapy candidate for the potential treatment of ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-264, a stem ...

(RTTNews) - Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has cleared the Investigational New Drug Application for VX-264, a stem cell-derived, fully differentiated pancreatic islet ...

The U.S. Food and Drug Administration (FDA) cleared Vertex Pharmaceuticals (NASDAQ:VRTX) investigational new drug (IND) application seeking to start a trial of cell therapy VX-264 to treat type 1 ...